Patent ID: 11865168
Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of eliciting an enhanced immune response comprising administering intravenously (IV) to a subject in need of prophylactic treatment of Mycobacterium tuberculosis (MTB) a pharmaceutical formulation comprising one or more modulating agents and Bacille Calmette-Guerin (BCG), wherein the one or more modulating agents are selected from the group consisting of an RNA encoding one or more MTB antigens selected from Ag85A and Ag85B, a viral vector encoding one or more MTB antigens selected from Ag85A and Ag85B, and one or more MTB antigens selected from Ag85A and Ag85B, and wherein the one or more modulating agents increase expression of IFNγ, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells; and
confirming an enhanced immune response was elicited in the subject, thereby providing an enhanced immune response for prophylactic treatment, by:
detecting an increased fractional or absolute number of Vγ9+ γδ T cells in a blood sample obtained from the subject; or
detecting an increased proportion of transitional (Ttm) memory cells compared to Central (Tcm) memory cells in a blood sample obtained from the subject.